New Membership: GCCIR joins IraSME and attends BMWi’s Innovation Day in Berlin

IMG_2494
Main stage at Innovation Day, photo by: Katelyn Petersen
IMG_3092
GCCIR Manager Katelyn Petersen testing a VR training module for hip replacement surgery, photo by: Jonas Kuhn

irasme logo_transparent

In light of the new Alberta-Europe Technology Collaboration Fund established by the Alberta Ministry of Economic Development and Trade (EDT) and the German-Canadian Centre for Innovation and Research (GCCIR), the GCCIR has joined the IraSME network.

IraSME is a network of ministries and funding agencies, which offer national and regional funding programs for cooperative research projects between small and medium-sized enterprises (SMEs). The network supports SMEs in their transnational innovation activities, and helps them access technological expertise, extend their own networks and bridge the gap between research and innovation.

Twice a year, IraSME issues calls for proposals for transnational cooperative research projects between SMEs and research and technology organizations (RTOs), with the objective of developing innovative products, processes and/or services in technological fields. The calls follow a bottom-up approach, meaning research topics are not pre-defined and are open to all technology sectors. Funding for collaboration projects is made available through national and regional funding programs administered by the respective ministry or funding agency participating in the IraSME network.

The IraSME membership provides the GCCIR with a unique tool to administer the Alberta-Europe Technology Collaboration Fund in Alberta, and to advise on respective funding agencies partnering companies could potentially apply to. The network will also benefit GCCIR in future matchmaking missions to Europe; missions the GCCIR offers to Albertan SMEs looking to find international collaboration partners.

Read the latest IraSME Newsletter containing the announcement of GCCIR’s membership here.

The official announcement of GCCIR’s membership in the IraSME network took place at Innovation Day, on June 7, 2018, in Berlin. It was an honor for GCCIR Manager Katelyn Petersen and Senior Project Coordinator Jonas Kuhn to travel to Germany and attend Innovation Day for this special occasion.

Also celebrating ZIM’s 10 years anniversary, this year’s Innovation Day had exceptional significance. With more than 300 companies and research institutes presenting a variety of innovations developed with the support of the German Federal Ministry of Economic Affairs and Energy (BMWi), and more than 2000 visitors and attendees, it was a particularly exciting and productive showcase of technology development and international coopertation.


Links:

https://irasme-cornet-berlin-2018.b2match.io/page-1561

https://www.zim.de/ZIM/Navigation/DE/Infothek/Veranstaltungen/veranstaltungen.html

Advertisements

GCCIR at Global Petroleum Show 2018: Minister Hon. Deron Bilous highlights impact of international R&D collaborations between SMEs

1528829088743_51555523-a235-4a60-808f-8c50056d4265
In the picture from left to right: Vladimir Mravcak (Chairman, Atlantis Research Labs), Hon. Deron Bilous (Minister of Economic Development and Trade), Dr. Andreas Sichert (CEO, Orcan Energy AG), and Markus Lintl (Head of Industry & New Business, Orcan Energy AG)

This month the GCCIR attended one of the biggest shows around technologies in the oil and gas sector, the Global Petroleum Show, in Calagry. Also attending were Orcan Energy AG from Germany and Atlantis Research Labs Inc. from Alberta. The two SMEs have recently entered into an innovative R&D collaboration. To learn about this new collaboration project and highlight the impact that the Albert government’s R&D funding programs have, Hon. Deron Bilous, Minister of Economic Development and Trade (EDT), stopped by the Orcan Energy AG and Atlantis Research Labs Inc.’s booths at the Global Petroleum Show.

The collaboration project Orcan Energy AG and Atlantis Research Labs Inc. have entered into is funded through the Alberta-Europe Technology Collaboration Fund, a program created by EDT and administered by the German-Canadian Centre for Innovation and Research (GCCIR) to support Albertan companies, foster economic growth in Alberta, and encourage international knowledge transfer between Alberta and Europe.

Interview with Dr. Chad Bousman

PRECISION MEDICINE

Chad_Bousman_320x350

Dr. Chad Bousman is Assistant Professor at the Department of Medical Genetics, Psychiatry, and Philosophy & Pharmacology at the University of Calgary and a member of the Alberta Children’s Hospital Research Institute. The broad vision of his research is to discover, develop, and evaluate genomic-based tools with the utility to guide clinical decision-making and improve mental health outcomes. His primary focus is on optimizing the selection and dosing of drug therapies used to treat depression and schizophrenia. Dr. Bousman is also actively involved in the research examining the interactive effect genes and environments have on the brains of those with mental health problems.

1) You work at the Alberta Children’s Hospital Research Institute at the University of Calgary. Can you tell us about the organization and if precision medicine already plays a big role there?

 The Alberta Children’s Hospital Research Institute (ACHRI) supports excellence in research, innovation and knowledge translation to improve the health and well-being of children from pre-conception to adulthood.  A multi-disciplinary institute of the University of Calgary, Alberta Health Services and the Alberta Children’s Hospital Foundation, the institute creates new knowledge to change practice and shape policy in ways that improve child health outcomes.

Precision medicine is medical care designed to optimize efficiency or therapeutic benefit for particular groups of patients, especially by using genetic or molecular profiling. The institute pursues precision medicine by assisting in the diagnosis of children with rare diseases and enabling individually-focused treatments, including pharmacogenomics where my lab sits. The importance of this research cannot be overstated. One in four children admitted to the Alberta Children’s Hospital is a patient with a hereditary illness. (i.e. arthritis, cystic fibrosis, sickle cell) The Alberta Children’s Hospital Research Institute is one of a few institutes in Canada which can provide rapid genetic testing of rare illnesses to provide meaningful answers to families and clinicians. We have been designated by the University of Calgary as the Centre for Health Genomics and Bioinformatics.  Our researchers can also provide experimental gene therapy for some specific disorders by engineering viruses that carry corrected proteins and reintroduce these cells into the patient through a bone marrow transplant.

More information about ACHRI can be found at: www.research4kids.ucalgary.ca

2) You focus on optimizing drug therapy to treat mental illnesses, especially depression and schizophrenia. Are there big differences using precision medicine in psychiatric care in comparison to other medical disciplines?  

Precision medicine encompasses a number of strategies for optimizing medical care and these strategies can differ across medical disciplines. The precision medicine strategy that my research focuses on is pharmacogenetics. Pharmacogenetics uses a person’s genetic information to assist doctors in the selection and dosing of medications. There is substantial overlap in how pharmacogenetics is used in psychiatric care and other medical disciplines. However, disciplines such as psychiatry, neurology, oncology, and cardiology are furthest along in the implementation of pharmacogenetics into clinical practice.

3) The costs of precision medicine seem to be higher than those of more traditional treatments. Is precision medicine also a question of money?

Costs are certainly a key concern when it comes to precision medicine but it is important to differentiate between short-term costs and long-term costs. In the short-term, the costs of delivering precision medicine is often higher than traditional treatment approaches because precision medicine is typically associated with the introduction of new technology or additional testing. However, clinical trials are now demonstrating that these upfront costs are off-set by the long-term cost-savings that precision medicine provides. For example, the cost of ordering a pharmacogenetic test prior to prescribing an antidepressant can range from $100-$500, a significant upfront cost relative to standard prescribing practice. However, this testing can assist doctors in selecting an antidepressant that has a higher probability of working for a particular individual, ultimately saving >$3,500 in direct medical costs over the person’s life.

4) If you compare the use of precision medicine worldwide how well is Canada doing?

The clinical use of precision medicine remains limited around the world. However, Canada along with a number of other countries are at the forefront of the precision medicine revolution. As with any new and bold initiative, precision medicine’s successes in Canada will depend heavily on the resources made available for research and implementation projects.

 5) What are the main challenges for precision medicine in the future?

Precision medicine is still early in its evolution and will require local and global collaborations to facilitate its transition into routine care. I think one of the biggest challenges will be redesigning healthcare systems to enable seamless integration of precision medicine into practice. This redesign will include education of healthcare providers and consumers on the use and limitations of precision medicine innovations, improvement of electronic health records, and the development of new treatment and prevention guidelines that are aligned with the precision medicine era.